Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.
By W. Sandborn, G. Van Assche, W. Reinisch, J. Colombel, G. D'Haens, D. Wolf, M. Kron, M. Tighe, A. Lazar, R. Thakkar. Gastroenterology, 2012
801 citations recorded by the source corpus.
Subfields: Epidemiology, Genetics, Hepatology
View Paper: https://www.semanticscholar.org/paper/4063c99bb146c564c289f54413e65791e2029f6f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Genetics
Citations in the corpus
- ACG Clinical Guideline: Ulcerative Colitis in Adults (2019, background): “In the ULTRA 2 trial, 494 patients with moderately to severely active UC were randomized to receive adalimumab or placebo (130).”